Clinical development platforms typically evolve with technology advances and scientific breakthroughs. Notably, the COVID-19 pandemic accelerated the adoption of digital technologies, data science, analytics, and automation tools, enabling remote services and preserving the continuity of care.
A unified clinical development platform with improved data architecture and analytics capabilities can accelerate the drug development process and enrich the experience for sponsors, patients, and physicians. In recent years, the industry has pivoted from questioning the existence of end-to-end platforms to creating a near-term vision for adopting such platforms.
Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022 looks at the vendor landscape of clinical development platforms and presents in-depth analysis and insights on these platforms. We assess the capabilities of 22 clinical development platform vendors and map them on the Everest Group PEAK Matrix®, a composite index of distinct metrics related to a vendor’s capability and market impact.
Scope
Industry: life sciences
Geography: global
Contents
In this report, we:
Examine the vendor landscape for clinical trial platforms and products
Assess 22 clinical development platform vendors on several capability and market success-related dimensions
